

Publications of the Week

SARS-CoV-2 Immune Evasion by the B.1.427/B.1.429 Variant of Concern

First Author: Matthew McCallum | Senior Author: David Veesler (pictured)  
Science | UW



CAL.20C (B.1.427/B.1.429) carries spike glycoprotein mutations S13I in the signal peptide, W152C in the N-terminal domain, and L452R in the receptor-binding domain. Plasma from individuals vaccinated with a Wuhan-1 isolate-based mRNA vaccine or convalescent individuals exhibited neutralizing titers, which were reduced against the B.1.427/B.1.429 variant relative to wildtype pseudoviruses.

[Abstract](#) | [Press Release](#)

Multiplexed Functional Genomic Analysis of 5' Untranslated Region Mutations Across the Spectrum of Prostate Cancer

First Author: Yiting Lim | Senior Author: Andrew Hsieh (pictured)  
Nature Communications | Fred Hutch and UW



The functional consequences of genetic variants within 5' untranslated regions (UTRs) on a genome-wide scale are poorly understood in disease. The authors develop a high-throughput multi-layer functional genomics method called pooled full-length UTR multiplex assay on gene expression to quantify the molecular consequences of somatic 5' UTR mutations in human prostate cancer. [Abstract](#) | [Press Release](#)

[View All Publications](#)

Awards

Dr. Anindya Roy Awarded WRF Translational Funding

Institute for Protein Design



The Washington Research Foundation (WRF) has awarded a \$250,000 Phase 2 technology commercialization grant to Dr. Anindya Roy (pictured) to further develop a novel miniprotein binder for the treatment of idiopathic pulmonary fibrosis. Dr. Roy, an Acting Instructor in David Baker's lab at the UW's Institute for Protein Design, is building on positive results from a WRF Phase 1 grant. [Read More](#)

Inaugural UW Presidential Scholarship Recipients

UW



The UW Presidential Scholarship, a special program launched in 2018 thanks to a founding endowment from William and Pamela Ayer, recognizes outstanding Washington state applicants to the UW who are already leaders in their communities. Recipient Ruth Mulugeta (pictured), a Seattle native studying molecular, cellular & developmental biology, shares her UW journey and plans for the future. [Read More](#)

[View All Featured Awards](#)

Local News

Fred Hutchinson Cancer Research Center, Seattle Children's and UW Medicine Lay Groundwork for Historic Cancer Partnership

Fred Hutch



Fred Hutch, UW Medicine, Seattle Cancer Care Alliance, and Seattle Children's have announced plans to explore restructuring their longtime relationship to accelerate a shared mission of advancing diagnosis, treatment and pioneering of cures for cancer. If finalized and approved, the proposed restructure would establish an adult-focused oncology program and, separately, a pediatric oncology program. [Read More](#)

FDA Approves Accelerated Dosing in Non-Hodgkin's Lymphoma/Leukemia Clinical Trial

AVM Biotechnology



AVM Biotechnology has announced FDA permission to modify its ongoing clinical study, AVM0703-001. The approved protocol modification involves the elimination of three of the six cohorts and reduction of the interval between cohorts. Eliminating the 9, 12 and 15 mg/kg dose requirements and moving directly to the anticipated effective clinical dose of 18 mg/kg is important for this study. [Read More](#)

Kineta Announces First Participant Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of KCP506

Kineta



Kineta has announced that the first participant has been successfully dosed in a Phase 1 multiple ascending dose clinical trial of KCP506, an investigational, first-in-class  $\alpha 9\alpha 10$  nicotinic acetylcholine receptor antagonist for the treatment of chronic neuropathic pain. The Phase 1, double blinded, placebo controlled, multiple ascending dose study is designed to evaluate KCP506 in healthy people. [Read More](#)

Aurion Biotech Appoints Dr. Shigeru Kinoshita to Its Medical Advisory Board


Aurion Biotech



Dr. Shigeru Kinoshita (pictured) has joined the medical advisory board at Aurion Biotech, whose mission is to cure blindness by developing a differentiated platform of advanced therapies to treat ocular diseases. Professor Kinoshita is the inventor of Aurion Biotech's lead candidate, cell therapy for the treatment of corneal endothelial disease. [Read More](#)

Deleted SARS-CoV-2 Sequences from Early in Wuhan Outbreak Offer Clues

Fred Hutch



Fred Hutch evolutionary biologist Dr. Jesse Bloom (pictured) reported uncovering SARS-CoV-2 sequences from early in the Wuhan outbreak that had been deleted from a National Institutes of Health database. He explained how he had recovered raw sequencing data from 34 samples from early Wuhan SARS-CoV-2 cases and used the data in the files to reconstruct partial sequences of 13 of those cases. [Read More](#)

US FDA Grants Regular Approval and Expands Indication for PADCEV®

Seagen



Seagen and Astellas Pharma have announced that the FDA has granted PADCEV® regular approval in the US, in addition to approving a new indication for adult patients with locally advanced or metastatic urothelial cancer who are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy. [Read More](#)

Seattle Children's Pioneering Immunotherapy Trial May Be Feasible to Combat Pediatric Brain and Spinal Cord Tumors

Seattle Children's



An innovative clinical trial led by Dr. Nicholas Vitanza (pictured), a neuro-oncologist at Seattle Children's, shows promise that delivering cancer-fighting chimeric antigen receptor T cells directly to the brain for children and young adults with recurrent or refractory brain and central nervous system tumors may be feasible and tolerable. [Read More](#)

[View All Articles](#) | [Submit an Article](#)

Upcoming Events in Seattle

- July 22 10:30 AM **Allen Institute Distinguished Seminar Series: Lin Tian**  
Online
- August 6 8:00 AM **Absher Kids' Cup**  
Washington National Golf Club
- August 10 11:00 AM **Science Says**  
Online
- August 17 5:00 PM **A Celeb-Studded Event to Support Research**  
Paramount Theatre
- August 20 4:00 PM **Life Science Washington Annual Summer Social**  
Online

[View All Events](#) | [Submit an Event](#)

Science Jobs in Seattle

- Research Technician, Infectious Diseases**  
Seattle Children's
- Therapy Area Leader, Discovery Research**  
Omeros
- Director, Commercial Training & Development**  
Adaptive Biotechnologies
- Research Administrator, Clinical Research**  
Fred Hutch
- Principle Scientist, Immuno-Oncology and Cellular Therapy**  
Bristol Myers Squibb

[View 121 Other Science Jobs](#) | [Submit a Job](#)



Submit your articles and events by reaching out to us at [info@scienceinseattle.com](mailto:info@scienceinseattle.com).

BROUGHT TO YOU BY



STEMCELL Technologies  
Products | Services

STEMCELL Science News  
Free Weekly Updates on Your Field

The Stem Cell Podcast  
Interviews and Updates on Stem Cell Science